NCT03443115 (DMD-HS) is a clinical trial in Duchenne Muscular Dystrophy, sponsored by Hôpital Cochin.

Who is sponsoring NCT03443115?

NCT03443115 is sponsored by Hôpital Cochin.

What condition does NCT03443115 study?

NCT03443115 studies Duchenne Muscular Dystrophy, Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy.

Is NCT03443115 still recruiting?

NCT03443115 is currently status unknown. Last updated 22 February 2018.

Last reviewed 2018-02-22 · How we verify

NCT03443115: DMD-HS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Duchenne Muscular Dystrophy Heart Study

Status unknown Last updated 22 February 2018

What this trial tests

trial in Duchenne Muscular Dystrophy in 700 participants. Status unknown.

Timeline

27 June 2017

Primary endpoint
16 February 2018

15 March 2020

Quick facts

Lead sponsor	Hôpital Cochin
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	700
Start date	27 June 2017
Primary completion	16 February 2018
Estimated completion	15 March 2020
Sites	1 location across France

Conditions studied

Duchenne Muscular Dystrophy — all drugs for Duchenne Muscular Dystrophy →
Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy — all drugs for Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy →

Sponsor

Hôpital Cochin

Who can join

Eligibility, male only, with Duchenne Muscular Dystrophy or Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retrospective cohort study including patients with genetically proven Duchenne muscular dystrophy, diagnosed from January 1993 to March 2020. Inclusion of the data relative to genetic diagnosis, clinical characteristics at baseline, cardiac and respiratory workup, medical treatments (ACE inhibitors, steroids), surgical procedures, and occurrence during follow-up of cardiac, respiratory and fatal events. Objectives are to describe long-term natural history of the disease, vital prognosis, genotype-phenotype correlations, effect of treatments.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future.
Łoboda A, Dulak J. · · 2020 · cited 57× · PMID 32691346 · DOI 10.1007/s43440-020-00134-x
Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data.
Porcher R, Desguerre I, Amthor H, Chabrol B, et al · · 2021 · cited 37× · PMID 33748842 · DOI 10.1093/eurheartj/ehab054
Predictors of cardiac disease in duchenne muscular dystrophy: a systematic review and evidence grading.
Landfeldt E, Alemán A, Abner S, Zhang R, et al · · 2024 · cited 6× · PMID 39342355 · DOI 10.1186/s13023-024-03372-x
Association between exon-skipping therapy with eteplirsen and cardiac outcomes in Duchenne muscular dystrophy.
Iff J, Desguerre I, Liu Y, Sarkozy F, et al · · 2026 · cited 2× · PMID 40831143 · DOI 10.1177/22143602251366721

Verify or expand the search:

Other recruiting trials for Duchenne Muscular Dystrophy

Currently open trials in the same condition.

NCT07287189 — Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients · Phase 2 · recruiting
NCT06817382 — A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Ma · Phase 1 · recruiting
NCT06402942 — Gamified Occupational Therapy for Adolescents With Duchenne Muscular Dystrophy · NA · recruiting
NCT06450639 — A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) · Phase 2 · active not recruiting
NCT06692426 — Trial of Cell Based Therapy for DMD · Phase 1 · recruiting

Other Hôpital Cochin trials

Trials by the same sponsor.

NCT04499001 — Effect of Pharmaceutical Consultations Just Before Rheumatology Consultations on Improving Knowledge and Skills for Pati · unknown
NCT03670108 — "SMS - Heals My Health" · unknown
NCT04879316 — Energy for Lymphocytes · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03443115 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hôpital Cochin
Last refreshed: 22 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03443115.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing